Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spironolactone and Dexamethasone in Moderate-to-severe COVID-19
NCT04826822Phase 3Unknown
- Sponsor
- Zabaykalsky Regional Clinical Hospital
- Start
- Feb 2021
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of spironolactone in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Zabaykalsky Regional Clinical Hospital. Primary endpoint: Evaluation of the clinical status at Day 14. Status: unknown.
02
Drugs
spironolactone
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04826822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04826822.